Similarly, upregulation of an IFN-γ-responsive gene expression signature appears to be important for the clinical success of anti–CTLA-4 mAb, as evidenced by the analysis of tumor specimens from melanoma patients treated with Ipilimumab (46). This evidence concerns the gene CTLA4 and neoplasm.